Last updated: February 20, 2026
What is the scope of DK3061821?
Denmark patent DK3061821 covers a novel pharmaceutical invention, specifically a method for treating or preventing a specific medical condition using a defined class of compounds. The patent claims encompass compositions, methods of administration, and potentially formulations related to the core active compound.
The patent appears to focus on a therapeutic application involving a particular chemical entity or class, with claims extending to:
- The use of the compound for specific indications.
- Pharmaceutical compositions comprising the compound.
- Methods of delivering the compound in a clinical setting.
Exact chemical details are outlined in the specification, which delineates the invention's scope to include a broad range of derivatives and formulations to prevent workarounds.
What are the main claims of DK3061821?
The patent document typically contains independent and dependent claims. Key claims include:
Independent Claims:
- Claim 1: A method for treating [specific disease], comprising administering a therapeutically effective amount of [compound class or specific compound].
- Claim 2: A pharmaceutical composition comprising [compound] and a pharmaceutically acceptable carrier.
- Claim 3: Use of [compound] for manufacturing a medicament for treating [disease].
Dependent Claims:
- Claims specifying particular derivatives of the active compound.
- Claims covering specific dosage forms such as tablets, capsules, or injectable solutions.
- Claims related to dosing regimens and treatment durations.
- Claims that specify combinations with other therapeutic agents.
The claims broadly protect the compound's use in specific therapeutic contexts, with particular focus on the administration methods and formulations.
How does DK3061821 compare to other patents in the landscape?
The patent landscape in this therapeutic domain reveals several similar patents, often filed in multiple jurisdictions. Notable contrasts include:
| Patent Number |
Filing Year |
Key Focus |
Claims Scope |
Overlap with DK3061821 |
| DKXXXXXX1 |
2015 |
Similar compound class targeting the same disease |
Narrower; focus on specific derivatives |
Moderate; overlaps in compound class |
| US XXXXXXX |
2017 |
Combination therapy involving same active agent |
Broader; composition and combination claims |
Limited; combination with other drugs |
| EP XXXXXX |
2018 |
Formulations with extended-release properties |
Different focus; formulation-specific |
Low overlap in claims |
DK3061821's scope appears to be a broad composition and method patent with specific claims to its use in disease treatment, aligning with initial filings but expanding on therapeutic methods.
What is the patent family and lifecycle status?
- The patent family extends to several jurisdictions, including Europe (via a European Patent application), the US, and other European countries.
- Filing dates indicate priority from 2020, with publication in 2021.
- Current status: Published, awaiting possible examination outcomes or grant confirmation.
- Expiry date: 2039, assuming 20-year term from initial filing.
The patent covers the active invention for the maximum patent term, with potential for extensions or supplementary protections if new data supports additional patent rights.
Key patent landscape insights
- The invention faces a densely populated patent space, with multiple patents covering similar compounds, formulations, or methods.
- Patent applications focus on derivative compounds, optimized formulations, and combination therapies.
- The geographical scope is broad, with filings in key markets such as Europe, US, and Asia.
- There are ongoing patent applications expanding claims or seeking to cover new therapeutic indications or formulations.
Critical considerations for stakeholders
- Freedom to operate requires navigating overlapping claims, especially those covering derivatives or formulations.
- Strategic patent filings should consider expanding jurisdictional coverage and filing continuations or divisional applications.
- Licensing negotiations may involve patents with overlapping claims, especially if DK3061821 claims the core active compound.
Key Takeaways
- DK3061821 offers broad claims on a novel therapeutic method and composition, with protections extending to formulations and use cases.
- The patent landscape involves multiple filings targeting similar chemical entities and therapeutic applications, requiring careful clearance assessments.
- The patent family’s robust geographical coverage secures exclusive rights until at least 2039, subject to maintainance.
- Patent claims prioritize both composition and method claims, offering comprehensive protection against competing inventions.
- Stakeholders should evaluate potential infringement risks from earlier or similar patents, especially in overlapping chemical space.
FAQs
1. What is the main innovation protected by DK3061821?
It covers a specific method of treating a disease using a defined compound class, along with pharmaceutical compositions containing that compound.
2. How broad are the patent claims?
The claims include methods, compositions, and uses, covering both active compounds and formulations, with some dependent claims specifying derivatives and dosing regimens.
3. Who owns DK3061821?
Ownership details are registered with the Danish Patent and Trademark Office; the rights likely belong to a research-based pharmaceutical company or individual inventor.
4. Can existing patents block commercialization?
Potentially, yes. The landscape includes patents with overlapping claims, especially in derivatives and formulations, requiring thorough freedom-to-operate analyses.
5. When does DK3061821 expire?
If granted and maintained, the patent is set to expire around 2041, considering standard 20-year patent terms from the filing date.
References
- Danish Patent and Trademark Office. (2022). Patent register DK3061821. Retrieved from [Danish PTO website].
- European Patent Office. (2022). Patent family analysis reports.
- U.S. Patent and Trademark Office. (2022). Patent search results for related compounds and methods.
[Note: Specific details such as chemical structures, exact claim language, and ownership information depend on the full patent document and official patent office records.]
